Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2018—ElitechGroup Molecular Diagnostics launched its Respiratory Bacterial Elite MGB Panel, a high-performance multiplex assay for the diagnosis of bacterial respiratory infections validated on the Elite InGenius sample-to-result system. The panel detects and differentiates in a single reaction M. pneumoniae, C. pneumoniae, and L. pneumophila.
April 2018—Mesa Biotech announced its Accula Flu A/Flu B test is FDA 510(k) cleared and CLIA waived. It is the company’s first flu A/flu B test cassette available in the U.S. The PCR test provides results in approximately 30 minutes. It will be marketed by Sekisui Diagnostics under the Silaris brand.
April 2018—Sciex Diagnostics announced the launch of the Citrine Triple Quad MS/MS and Citrine Qtrap MS/MS systems for clinical diagnostics. The Citrine MS/MS system enables the measurement of trace levels of biomarkers and metabolites at sub-pg/mL concentrations, comprehensive multianalyte panels, and the measurement of large and small molecules.
April 2018—Roche will acquire San Diego–based Ignyta for $27.00 per share in cash, or $1.7 billion. Ignyta, which will continue its operations in San Diego, focuses on precision medicine in oncology aiming to test, identify, and treat patients with cancers harboring specific rare mutations.
April 2018—LGC Maine Standards announced it has enhanced the Validate THY linearity and calibration verification kit by adding free triiodothyronine (FT3) as a component of total triiodothyronine (TT3).
April 2018—One year after its establishment, the Blood Profiling Atlas in Cancer consortium announced the public release of an initial dataset aimed at speeding the development and approval of liquid biopsy technologies. The dataset resides in the BloodPAC data commons and was developed to deepen the understanding of a patient’s cancer and accelerate the development of liquid biopsy technology to improve the outcomes of patients with cancer.
April 2018—Advanced Instruments announced the availability of its Osmo1 Single-Sample Micro-Osmometer. It is suited for clinical laboratories that directly draw and test small sample volumes and was designed specifically to improve efficiency and reduce sample turnaround time.
April 2018—Siemens Healthineers received FDA 510(k) clearance for its blood urea nitrogen and total carbon dioxide point-of-care tests to aid in the diagnosis of renal diseases and metabolic imbalances.
April 2018—LGC Maine Standards released two Validate linearity and calibration verification kits. The Validate Procalcitonin kit for Roche Cobas analyzers is in a human-serum matrix. The Validate HbA1c kit is for Tosoh analyzers and is in a human, whole blood matrix.
April 2018—Thermo Fisher Scientific has expanded its Oncomine portfolio with two assays for liquid biopsy and immuno-oncology for clinical research. The company also announced its next-generation Ion AmpliSeq HD technology. The Ion Torrent Oncomine Pan-Cancer Cell-Free Assay enables reproducible detection and analysis of tumor DNA and RNA across all major classes of somatic mutations (SNVs, indels, CNVs, and fusions) from a single vial of blood, with as little as 1 ng of nucleic acid input, within two days.
